



(43) International Publication Date
7 March 2013 (07.03.2013)

(10) International Publication Number
WO 2013/030168 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/EP2012/066632

(22) International Filing Date:
28 August 2012 (28.08.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11179500.1 31 August 2011 (31.08.2011) EP

(71) Applicants (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **VIB VZW** [BE/BE]; Rijnvisschestraat 120, B-9052 Gent (BE). **LIFE SCIENCES RESEARCH PARTNERS VZW** [BE/BE]; Campus Gasthuisberg, Herestraat 49, bus 913, B-3000 Leuven (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DE HAAS, Sanne, Lysbet** [NL/CH]; Wilhelm His-Strasse 1, CH-4056 Basel (CH). **DELMAR, Paul** [FR/CH]; Hammerstrasse 89, CH-4057 Basel (CH). **LAMBRECHTS, Diether** [BE/BE]; Ernest-Solvaystraat 55, B-3010 Kessel-lo (Leuven) (BE). **SCHERER, Stefan** [DE/US]; 1 DNA Way, South San Francisco, CA 94080 (US).

(74) Agent: **BRODBECK, Michel**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY

(57) Abstract: The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.



WO 2013/030168 A1